Other oral mucosal sites may also be affected
A once-weekly dosing interval may offer several practical advantages, including: Potentially improved patient adherence compared with daily injections an association observed with other once-weekly incretin therapies, though direct adherence data for retatrutide are not yet available Relatively stable plasma drug levels between doses, which may help reduce the peaks and troughs that can contribute to side effects Consistent pharmacodynamic effects throughout the week, supporting sustained appetite suppression and metabolic activity In Phase 2 trials (Jastreboff et al., NEJM , 2023), retatrutide was studied across a range of doses up to 12 mg once weekly, with structured dose-escalation protocols used to improve tolerability a strategy commonly employed with incretin-based therapies to minimise gastrointestinal side effects such as nausea, vomiting, and diarrhoea during initiation
Delivering Better Oral Health Chapter 12: Alcohol (CMO 14-unit guidance)
Estas afirmaciones no han sido evaluadas por la Food and Drug Administration
doi: 10.1210/endrev/bnae009
Always verify calculations match your specific research compound and protocols
